Dr. Ma mentioned key findings which have been shared up to now this yr on the subject of evolving therapy methods for sufferers with high-risk pores and skin most cancers.
Through the first half of 2025, a number of key updates have been shared on evolving therapy methods for sufferers with high-risk cutaneous squamous cell carcinoma and melanoma, two distinct types of pores and skin most cancers.
“Many findings [in skin cancer that were shared] this yr had been actually simply affirming what we have been doing for the previous few years,” Dr. Vincent Ma, a school member within the Division of Hematology, Medical Oncology and Palliative Care on the College of Wisconsin, stated of those therapy updates in an interview with CURE.
Within the interview, he mentioned a number of the most notable updates up to now this yr relating to therapy methods for sufferers with high-risk cutaneous squamous cell carcinoma, in addition to highlighted easy methods to scale back the danger of pores and skin most cancers recurrence in sufferers with this illness.
Furthermore, Ma, who can be an assistant professor throughout the Division of Medication and is a school affiliate of the Division of Dermatology, all on the College of Wisconsin, Faculty of Medication and Public Well being, shared extra on the this subject in one other article with CURE.
CURE: What have been a number of the most notable updates up to now this yr relating to therapy methods for sufferers with high-risk cutaneous squamous cell carcinoma?
Ma: On the 2025 ASCO Annual Assembly this yr, we truly had some very attention-grabbing updates about how we take into consideration treating sufferers with high-risk cutaneous squamous cell carcinoma. Squamous cell carcinoma of the pores and skin is the second most typical pores and skin most cancers in the US, and we all know {that a} good proportion of sufferers even have high-risk illness.
Excessive-risk means a really excessive danger of coming again after surgical procedure. The present normal of take care of sufferers with high-risk squamous cell carcinoma of the pores and skin is surgical procedure adopted by radiation remedy. However what we actually do not know on this explicit house is that if there’s any profit to giving any therapies after surgical procedure and after radiation to stop the pores and skin most cancers from coming again. We all know that about 30% of sufferers at 5 years with high-risk squamous cell pores and skin most cancers truly expertise recurrence. So, [we ask ourselves]: is there a approach that we will stop the recurrence of the pores and skin most cancers?
What potential approaches are being explored to cut back the danger of pores and skin most cancers recurrence in sufferers with high-risk squamous cell carcinoma?
There have been truly two trials that had been effectively highlighted this yr to look and reply that exact query. One in all them is named the KEYNOTE-630 trial, and the opposite one is named the C-POST trial. Each of these trials need to see if there’s a position for giving immunotherapy, particularly anti-PD-1 remedy, after surgical procedure and after radiation so as to stop recurrence of squamous cell pores and skin most cancers. Just a bit background on that: anti-PD-1 remedy is definitely FDA accredited proper now to deal with superior stage squamous cell pores and skin most cancers. Which means pores and skin most cancers that has unfold and is not eligible for surgical procedure. We’re, after all, making an attempt to see if we will convey that into the adjuvant setting to assist stop recurrence.
KEYNOTE-630 was a trial that checked out giving adjuvant Keytruda (pembrolizumab), which is anti-PD-1 remedy. They checked out giving it for a full yr period for half the sufferers that had been studied, and the opposite half of the sufferers obtained placebo. What they ended up discovering was that there was no statistical distinction by way of recurrence-free survival between the 2 arms. So there was no distinction by way of recurrence between those that acquired adjuvant Keytruda for one yr versus placebo. That was an attention-grabbing discovering from there.
In distinction, after we appeared on the C-POST examine, we truly found that these sufferers who, for instance, acquired anti-PD-1 remedy — within the case of the C-POST examine, it was Libtayo (cemiplimab) — and so they additionally in contrast it to an arm of sufferers who acquired placebo, they really discovered statistical significance by way of illness recurrence. It was very attention-grabbing to type of see that two research, you already know, studied an identical drug, which is anti-PD-1 remedy, and so they each had an identical comparability arm, which is placebo.
One examine specifically, which was the C-POST examine, had a disease-free survival profit. It’s totally attention-grabbing to notice that. What was additionally very attention-grabbing between the 2 research was that there have been slight variations by way of nuances between the affected person inhabitants that was analyzed, in addition to the endpoints that they had been analyzing.
Total, I feel the conclusion from the examine is that as a result of we noticed a disease-free survival profit from sufferers who obtained adjuvant Libtayo for one yr within the C-POST examine, it’s prone to finally grow to be normal of care sooner or later for sufferers who’ve high-risk squamous cell carcinoma of the pores and skin following surgical procedure and radiation.
To shut, what ought to sufferers with melanoma or high-risk cutaneous squamous cell carcinoma take away from in the present day’s dialog?
Many findings [in skin cancer that were shared] this yr had been actually simply affirming what we have been doing for the previous few years. This contains, first, for sufferers who’ve superior stage melanoma, the usual of care ought to primarily be immunotherapy within the first-line setting. Updates had been introduced from the DREAMseq examine, which is a landmark examine that confirmed that for sufferers with unresectable BRAF-mutated melanoma, the choice must be immunotherapy first, somewhat than BRAF/MEK focused remedy. The five-year follow-up information was introduced at ASCO this yr, and what they confirmed and confirmed is that sufferers handled with immunotherapy had an extended period of profit from therapy, had much less metastases to the mind, and beginning with immunotherapy permits for a greater response to later traces of therapy if their melanoma progresses.
One other vital level is the long-term follow-up from TIL remedy. TIL remedy was FDA accredited in 2024, and the five-year follow-up information was introduced. To offer some background on TIL remedy, it’s FDA accredited for superior stage melanoma sufferers whose illness has progressed on normal immunotherapy and focused remedy therapy. What was introduced at ASCO this yr was the five-year follow-up information, which confirmed that the long-term profit from TIL remedy for individuals who responded continues to stay vital. That was a significant spotlight from ASCO this yr.
One other vital spotlight general from the RELATIVITY-098 trial is that anti-PD-1 monotherapy following resection stays the usual of take care of adjuvant therapy of melanoma. The ultimate spotlight is that persevering with anti-PD-1 based mostly remedy for at the very least two years continues to stay the usual of take care of first-line therapy of superior stage melanoma.
Lastly, that adjuvant therapy with anti-PD-1 remedy with Libtayo is prone to grow to be a regular of care choice for particular high-risk cutaneous squamous cell carcinoma sufferers.
Transcript has been edited for readability and conciseness
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
